CADL - NASDAQ
Candel Therapeutics, Inc.
$8.80
+4.5%Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
At a Glance
Live Snapshotcadl
Total Debt
Last Annual Value
1.90M
3-Year CAGR
-56%
5-Year CAGR
15%
10-Year CAGR
16%
Candel Therapeutics, Inc. Competitors Analysis of Total Debt
| Company | Total Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Candel Therapeutics, Inc. NASDAQ:CADL | 1.90M | -56.3% | 27.7% | N/A | |
 Kyverna Therapeutics, Inc. NASDAQ:KYTX | 29.03M | 47.3% | 39.2% | N/A | |
 Aardvark Therapeutics, Inc. Common Stock NASDAQ:AARD | 441.00K | 39.6% | N/A | N/A | |
 Galectin Therapeutics Inc. NASDAQ:GALT | 133.74M | 23.0% | 35.7% | N/A | |
 Aldeyra Therapeutics, Inc. NASDAQ:ALDX | 15.53M | -0.3% | -0.4% | 28.0% | |
 Cabaletta Bio, Inc. NASDAQ:CABA | 27.10M | 75.4% | N/A | N/A | |
 Editas Medicine, Inc. NASDAQ:EDIT | 76.71M | 16.5% | 23.8% | 8.1% | |
 Capricor Therapeutics, Inc. NASDAQ:CAPR | 20.94M | 110.8% | 48.8% | 4.2% | |
8.25M | -65.0% | 10.9% | N/A | ||
 Genelux Corporation NASDAQ:GNLX | 1.69M | -12.5% | -41.8% | N/A |
Candel Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your CADL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.